Sangrado y mortalidad en el reemplazo valvular aórtico por catéter

New Devices for Percutaneous Treatment of Native Aortic Regurgitation: Expanding Horizons

Severe aortic regurgitation (AR) may account for 20% to 30% of all surgical aortic valve replacements (SAVR) and is often associated with aortic stenosis (AS). Transcatheter treatment of these patients is limited due to anatomical factors such as root and annular dilation, large annular dimensions, and less calcification in the valve leaflets to serve as<a href="https://solaci.org/en/2023/06/26/new-devices-for-percutaneous-treatment-of-native-aortic-regurgitation-expanding-horizons/" title="Read more" >...</a>

TAVI in Moderate Aortic Stenosis with Low Ejection Fraction

The presence of aortic stenosis, heart failure, and decreased ventricular function is associated with poor prognosis and high mortality. For this reason, both European and American guidelines classify severe stenosis as a Class I indication. There are two retrospective analyses that demonstrate the benefits of transcatheter aortic valve implantation (TAVI) via transfemoral access. The TAVR<a href="https://solaci.org/en/2023/06/16/tavi-in-moderate-aortic-stenosis-with-low-ejection-fraction/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

TAVR: Does HALT Affect Follow-Up?

Transcatheter aortic valve replacement (TAVR) in low-risk patients has been shown to be superior or noninferior in randomized studies, but the presence of valvular thrombosis, in its different forms, has not been well analyzed, nor is there much information on its impact on evolution. Researchers conducted an analysis of the LTR study that included 200<a href="https://solaci.org/en/2023/06/07/tavr-does-halt-affect-follow-up/" title="Read more" >...</a>

Síndrome de Tokotsubo ¿El género tiene influencia en su pronóstico?

Abbreviated Therapy in Patients with Acute Coronary Syndrome: How Safe Is Conservative DAPT Treatment?

Abbreviated dual antiplatelet therapy in patients at high risk for bleeding and acute myocardial infarction. Patients with acute coronary syndrome (ACS) who undergo stent placement (percutaneous coronary intervention, PCI) conventionally require at least 12 months of dual antiplatelet therapy (DAPT) to reduce ischemic events. Patients with ACS who are also at high risk for bleeding<a href="https://solaci.org/en/2023/06/01/abbreviated-therapy-in-patients-with-acute-coronary-syndrome-how-safe-is-conservative-dapt-treatment/" title="Read more" >...</a>

Impact of Right Ventricular Pacing in Patients with Permanent Pacemaker Implantation after TAVR

Permanent pacemaker implantation (PPI) is a relevant complication in patients undergoing transcatheter aortic valve replacement (TAVR) despite there being new devices. The current information on the long term impact of this complication remains unclear and recent evidence suggests post-TAVR ventricular pacing (VP) might be associated to higher risk of all-cause mortality and hospitalization for cardiac<a href="https://solaci.org/en/2023/05/28/impact-of-right-ventricular-pacing-in-patients-with-permanent-pacemaker-implantation-after-tavr/" title="Read more" >...</a>

EuroPCR 2023 | ACURATE Neo2: Results After 5 Years

The ACURATE Neo2 valve is an evolution of the first-generation ACURATE Neo valve with a low rate of pacemaker implantation and a decrease in paravalvular leak, also compatible with the 14F introducer. This prospective study included patients with symptomatic severe aortic stenosis at high surgical risk who underwent ACURATE Neo2 valve implantation. The primary endpoint<a href="https://solaci.org/en/2023/05/23/europcr-2023-acurate-neo2-results-after-5-years/" title="Read more" >...</a>

EuroPCR 2023 | Intravascular Lithotripsy (IVL) Balloon in the Treatment of Underexpanded Stents

Calcified coronary plaque (CCP) is a challenge for interventional cardiology. Stent underexpansion (SU) commonly associated with CCP could predispose to stent thrombosis or restenosis. Currently, SU in severe CCP can be treated by rotational atherectomy, orbital atherectomy, balloon cutting/scoring, non-compliant high-pressure balloons, or intravascular lithotripsy (IVL). The aim of this meta-analysis was to determine the<a href="https://solaci.org/en/2023/05/22/europcr-2023-intravascular-lithotripsy-ivl-balloon-in-the-treatment-of-underexpanded-stents/" title="Read more" >...</a>

EuroPCR 2023 | More Evidence in Favor of Renal Denervation

This study included 219 patients with uncontrolled essential hypertension who had received at least two antihypertensive drugs. All of them underwent a renal angiography and were randomized to the renal denervation group or the control group. Denervation was performed using the SyMapCath I catheter and the SYMPIONEER S1 generator/stimulator. Mean patient age was 45 years old, and<a href="https://solaci.org/en/2023/05/21/europcr-2023-more-evidence-in-favor-of-renal-denervation/" title="Read more" >...</a>

EuroPCR 2023 |Chimney Stenting vs BASILICA for the Prevention of Coronary Obstruction during TAVR

Coronary obstruction is a complication from TAVR that can cause death (up to 50% mortality), even though its incidence is lower than 1%.  One of the most frequent strategies used in the prevention of this complication is chimney stenting in patients at high anatomical risk (valve in valve, narrow sinotubular junction, short coronary ostium height).<a href="https://solaci.org/en/2023/05/17/europcr-2023-chimney-stenting-vs-basilica-for-the-prevention-of-coronary-obstruction-during-tavr/" title="Read more" >...</a>

EuroPCR 2023 |TAVR in Cardiogenic Shock

Patients presenting aortic stenosis with cardiogenic shock are at extreme risk, with 70% mortality until the aortic obstruction is resolved, and taking into account they make poor transplant candidates. Safety and efficacy of TAVR in patients with cardiogenic shock remains unclear. The aim of this study was to assess events in patients undergoing TAVR with<a href="https://solaci.org/en/2023/05/17/europcr-2023-tavr-in-cardiogenic-shock/" title="Read more" >...</a>